Research progress on the effect of antibiotics and proton pump inhibitors on immunotherapy of lung cancer through intestinal flora
- VernacularTitle:抗生素及质子泵抑制剂经肠道菌群影响肺癌免疫治疗的研究进展
- Author:
Qi WANG
1
;
Fei SUN
1
;
Yibo SHAN
1
;
Hongcan SHI
1
Author Information
1. 1. Clinical Medical College, Yangzhou University, Yangzhou, 225009, Jiangsu, P. R. China 2. Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225009, Jiangsu, P. R. China 3.Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou, 225009, Jiangsu, P. R. China
- Publication Type:Journal Article
- Keywords:
Immmune checkpoint inhibitor;
antibiotics;
proton pump inhibitor;
lung cancer;
intestinal flora;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(03):462-466
- CountryChina
- Language:Chinese
-
Abstract:
The treatment of patients with advanced lung cancer has been revolutionized with the advent of immunotherapy. However, not all patients can benefit equally from immunotherapy. In recent years, the relationship between intestinal flora and the efficacy of immunotherapy has gradually attracted scholars' attention. During the treatment of immune checkpoint inhibitors, the use of antibiotics, proton pump inhibitors and other drugs will affect the patient's intestinal flora, thus affecting the efficacy of immune checkpoint inhibitors, leading to poor prognosis of patients. This review will discuss that antibiotics and proton pump inhibitors reduce the efficacy of immunotherapy by affecting the diversity of intestinal flora, in order to facilitate the rational use of related drugs in clinical practice and improve the patient's outcomes.
